Source / episode info

• **Episode:**156
• **Title:**Divine Intervention Episode 156 – USMLE Step 2CK Rapid Review Series 16 (OBGYN).
• **Published:**2019-09-22
• Source:Episode page

One-liner

This episode reviews high-yield OBGYN topics focusing heavily on breast pathology, including screening guidelines, the workup of suspicious masses, appropriate hormone therapy based on menopausal status and receptor status (ER/PR), and management of metastatic disease.

High-yield summary

• Breast Mass Workup: For any palpable or visualized breast mass, initial evaluation requires a mammogram. If the patient is <30 years old, an ultrasound is preferred. Biopsy is required for suspicious findings (e.g., solid masses on US).
• Risk Factors: Increased risk includes personal/family history of breast cancer, BRCA mutations, and prolonged lifetime estrogen exposure (early menarche, late menopause, multiple pregnancies).
• Inflammatory Breast Cancer (IBC): Classic presentation involves a rapidly enlarging mass with skin changes, often described as "peau d'orange" or "powder ranger appearance," involving the dermal lymphatics.
• Hormone Therapy: Pre-menopausal women with ER+ cancer receive Tamoxifen (estrogen receptor antagonist on breast tissue). Post-menopausal women receive Aromatase Inhibitors (e.g., anastrozole) to decrease systemic estrogen production, as Tamoxifen is less effective/appropriate in this group.
• Surgical Management: The standard approach for staging involves a Sentinel Lymph Node Biopsy (SLNB) rather than a full Axillary Lymph Node Dissection (ALND), due to the significantly lower risk of lymphedema.
• Screening Guidelines: While USPSTF recommends starting at age 50, many board exams test the American Cancer Society guideline: screening mammogram every year starting at age 40.

Learning objectives

• Differentiate appropriate initial imaging modalities for various age groups presenting with breast masses.
• Identify the key risk factors and genetic predispositions associated with breast carcinoma.
• Select the correct endocrine therapy based on the patient's menopausal status (pre- vs post-menopausal) and receptor status (ER/PR).
• Outline the appropriate staging workup for a suspicious breast mass, including the role of SLNB versus ALND.
• Recognize clinical signs suggestive of Inflammatory Breast Cancer (IBC).